luvadaxistat
Small moleculeexperimental
Clinical trial activity
11 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2015 (NCT02566759)
Timeline
Indications
Mechanism of action
- D-amino-acid oxidaseINHIBITOR
DAO inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=c1[nH]nc(CCc2ccc(C(F)(F)F)cc2)cc1O- Mol. weight
- 284.24 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2338801 ↗
Also known as
- tak-831
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05182476 | Phase 2 | Dec 7, 2021 | Neurocrine Biosciences |
| NCT04234672 | Phase 1 | Feb 3, 2020 | Takeda |
| NCT03706469 | Phase 1 | Oct 18, 2018 | Millennium Pharmaceuticals |
| NCT03687684 | Phase 1 | Oct 9, 2018 | Takeda |
| NCT03382639 | Phase 2 | Dec 22, 2017 | Millennium Pharmaceuticals |
| NCT03359785 | Phase 2 | Dec 21, 2017 | Takeda |
| NCT03214588 | Phase 2 | Nov 8, 2017 | Takeda |
| NCT03224325 | Phase 1 | Jul 21, 2017 | Takeda |
| NCT03101293 | Phase 1 | Mar 29, 2017 | Takeda |
| NCT02716987 | Phase 1 | Apr 1, 2016 | Takeda |
| NCT02566759 | Phase 1 | Oct 1, 2015 | Takeda |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 8 | 8 | 2 | 2015 |
| Millennium Pharmaceuticals | For profit | 2 | 2 | 2 | 2017 |
| Neurocrine Biosciences | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1